Keshavarz F.a· Soltani M.b· Mokhtarian K.a· Beshkar P.c· Majidi J.d· Azadegan-Dehkordi F.a· Anjomshoa M.e· Bagheri N.f

Author affiliations

aCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
bStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran
cClinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
dMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
eDepartment of Anatomical Sciences, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
fDepartment of Microbiology and Immunology, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: February 21, 2022
Accepted: July 16, 2022
Published online: September 19, 2022

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Abstract

Background: Schizophrenia is a disease of the nervous system, and immune system disorders can affect its pathogenesis. Activation of microglia, proinflammatory cytokines, disruption of the blood-brain barrier due to inflammation, activation of autoreactive B cells, and consequently the production of autoantibodies against system antigens are among the immune processes involved in neurological diseases. Interleukin-32 (IL-32) is a proinflammatory cytokine that is essential in activating innate and adaptive immune responses. This study aimed to measure the serum level of IL-32 as well as the frequency of autoantibody positivity against several nervous system antigens in patients with schizophrenia. Material and Methods: This study was conducted on 40 patients with schizophrenia and 40 healthy individuals in the control group. Serum IL-32 levels were measured by ELISA. The frequency of autoantibodies against Hu, Ri, Yo, Tr, CV2, amphiphysin, SOX1, Zic4, ITPR1, CARP, glutamic acid decarboxylase GAD, recoverin, titin, and ganglioside antigens was measured by the indirect immunofluorescence method. Results: Serum IL-32 levels in patients with schizophrenia were significantly higher compared to the control group. The frequency of autoantibodies against GAD and RI antigens in patients with schizophrenia was significantly higher than in the control group. Autoantibodies were positive in 8 patients for GAD antigen and 5 patients for RI antigen. Autoantibodies were also positive in 2 patients for CV2, 1 patient for Hu, and 1 patient for CARP. Negative results were reported for other antigens. Conclusion: Our findings suggest that elevated the serum IL-32 level and autoantibodies against GAD and RI antigens may be a reflection of immune system dysregulation in patients with schizophrenia.

© 2022 S. Karger AG, Basel

References Ng QX, Soh AYS, Venkatanarayanan N, Ho CYX, Lim DY, Yeo W-S. A systematic review of the effect of probiotic supplementation on schizophrenia symptoms. Neuropsychobiology. 2019;78(1):1–6. Parakh P, Basu D. Cannabis and psychosis: have we found the missing links? Asian J Psychiatr. 2013;6(4):281–7. Budisteanu M, Andrei E, Linca F, Hulea DS, Velicu AC, Mihailescu I, et al. Predictive factors in early onset schizophrenia. Exp Ther Med. 2020;20(6):210. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–70. van Kesteren CFMG, Gremmels H, de Witte LD, Hol EM, Van Gool AR, Falkai PG, et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiatry. 2017;7(3):e1075. Margari F, Petruzzelli MG, Mianulli R, Toto M, Pastore A, Bizzaro N, et al. Anti-brain autoantibodies in the serum of schizophrenic patients: a case-control study. Psychiatry Res. 2013;210(3):800–5. Jones AL, Mowry BJ, McLean DE, Mantzioris BX, Pender MP, Greer JM. Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. J Neuroimmunol. 2014;269(1–2):68–75. Whelan R, St Clair D, Mustard CJ, Hallford P, Wei J. Study of novel autoantibodies in schizophrenia. Schizophr Bull. 2018;44(6):1341–9. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709. Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019;10(1):5816–7. Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20(2):136–44. Li Q, Michel K, Annahazi A, Demir IE, Ceyhan GO, Zeller F, et al. Anti-Hu antibodies activate enteric and sensory neurons. Sci Rep. 2016;6(1):38216. Han S, Yang Y. Interleukin-32: frenemy in cancer? BMB Rep. 2019;52(3):165–74. Tsai C-L, Chiu Y-M, Lee Y-J, Hsieh C-T, Shieh D-C, Tsay GJ, et al. Interleukin-32 plays an essential role in human calcified aortic valve cells. Eur Cytokine Netw. 2018;29(1):36–47. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13(2):261–76. Kroken RA, Sommer IE, Steen VM, Dieset I, Johnsen E. Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics. Front Psychiatry. 2018;9:753. Pouget JG. The emerging immunogenetic architecture of schizophrenia. Schizophrenia Bulletin. 2018;44(5):993–1004. Reale M, Costantini E, Greig NH. Cytokine imbalance in schizophrenia. From research to clinic: potential implications for treatment. Front Psychiatry. 2021;12:536257. de Albuquerque R, Komsi E, Starskaia I, Ullah U, Lahesmaa R. The role of Interleukin-32 in autoimmunity. Scand J Immunol. 2021;93(2):e13012. Bae S, Kim YG, Choi J, Hong J, Lee S, Kang T, et al. Elevated interleukin-32 expression in granulomatosis with polyangiitis. Rheumatology. 2012;51(11):1979–88. Yao Q, Wang B, Jia X, Li Q, Yao W, Zhang JA. Increased human interleukin-32 expression is related to disease activity of Graves’ disease. Front Endocrinol. 2019;10:613. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, et al. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis. 2011;70(4):660–7. Wojciechowska JK, Koscielska-Kasprzak K, Krajewski W, Morawski K. Serum levels of interleukin-32 and interleukin-6 in granulomatosis with polyangiitis and microscopic polyangiitis: association with clinical and biochemical findings. Eur Cytokine Netw. 2019;30(4):151–9. Kallionpaa H, Somani J, Tuomela S, Ullah U, de Albuquerque R, Lonnberg T, et al. Early detection of peripheral blood cell signature in children developing beta-cell autoimmunity at a young age. Diabetes. 2019;68(10):2024–34. Schizophrenia Working Group of the Psychiatric Genomics Consortium; Neale BM, Corvin A, Walters JT, Farh K-H, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7. Pollak TA, Beck K, Irani SR, Howes OD, David AS, McGuire PK. Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology. 2016;233(9):1605–21. Grain R, Lally J, Stubbs B, Malik S, LeMince A, Nicholson TR, et al. Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: a systematic review, meta-analysis, and case series. Psychiatry Clin Neurosci. 2017;71(10):678–89. Sedley L. Advances in Nutritional Epigenetics: a fresh perspective for an old idea. Lessons learned, limitations, and future directions. Epigenet Insights. 2020;13:2516865720981924. Vinke AM, Schaper FLWVJ, Vlooswijk MCG, Nicolai J, Majoie MHJM, Martinez Martinez P, et al. Anti-GAD antibodies in a cohort of neuropsychiatric patients. Epilepsy Behav. 2018;82:25–8. Haussleiter IS, Wandinger K-P, Juckel G. A case of GABAR antibodies in schizophrenia. BMC Psychiatry. 2017;17(1):9. Zhang Z, Wu J, Xu D, Zhao S, Lian D, Zhang D, et al. Anti-Ri-related possible autoimmune encephalitis may cause intellectual and developmental disabilities in pediatric patients: a case report. 2021. Bilgen Ulgar Ş, Ayaydın H, Çelik H, Koyuncu İ, Kirmit A. Evaluation of antineuronal antibodies and 8-OHdG in mothers of children with autism spectrum disorder: a case-control study. Int J Psychiatry Clin Pract. 2021:1–7. Epub ahead of print. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76(1):82–94. Mantere O, Saarela M, Kieseppä T, Raij T, Mäntylä T, Lindgren M, et al. Anti-neuronal anti-bodies in patients with early psychosis. Schizophr Res. 2018;192:404–7. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13(1):282. Naides SJ. The role of the laboratory in the expanding field of neuroimmunology: autoantibodies to neural targets. J Immunol Methods. 2018;463:1–20. Weis S, Sonnberger M, Dunzinger A, Voglmayr E, Aichholzer M, Kleiser R, et al. Autoimmune encephalitis: paraneoplastic syndromes. Imaging brain diseases. Springer; 2019. p. 2139–65. Nordentoft M, Plana-Ripoll O, Laursen TM. Cancer and schizophrenia. Curr Opin Psychiatry. 2021;34(3):260–5. Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders: insights and challenges. Nat Rev Neurol. 2020;16(7):353–65. Jernbom Falk A, Galletly C, Just D, Toben C, Baune BT, Clark SR, et al. Autoantibody profiles associated with clinical features in psychotic disorders. Transl Psychiatry. 2021;11(1):474–9. Article / Publication Details

First-Page Preview

Received: February 21, 2022
Accepted: July 16, 2022
Published online: September 19, 2022

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.